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Assessment of the value of 
youth work in Ireland 
The National Youth Council of Ireland (NYCI) recently published 
what they claim to be the first national comprehensive and 
rigorous economic assessment of youth work in Ireland.1 The 
fieldwork and data collection and analysis were undertaken by 
Indecon International Economic Consultants. 
The nature and extent of youth work in Ireland
The vast majority (80%) of youth work 
organisations provide recreational, arts and 
sports-related activities; over half provide 
activities focused on the welfare and well-
being of young people, including measures 
that address substance misuse and early 
school-leaving; some provide activities to 
divert young people from crime and anti-
social behaviour. 
An estimated 312,615 young people aged 
between 10 and 24 participated in youth work 
during 2011; this figure represents 43.3% of 
this age cohort nationally; 54% of participants 
were female and 53.3% were believed to be 
socially or economically disadvantaged. 
There are over 40 national youth work 
organisations in the sector responsible for 
providing services through local community-
based projects and groups. It is estimated 
that 40,145 individuals work in a voluntary 
capacity in the sector and 1,397 full-time 
equivalents are employed in management, 
service delivery and training and support  
for volunteers. 
The youth work sector received almost €79 million in public funding during 2011; the 
Department of Children and Youth Affairs (DCYA) provided €61.5 million, the Irish Youth Justice 
Service (IYJS) €8.8 million and the Health Service Executive (HSE) €8.3 million. This represents 
an investment by the State of €206 per young person participating in youth work activities in 
2011. 
A cost-benefit analysis of youth work
The economic assessment was guided by the following question: What would be the likely 
outcomes for young people participating in justice-, health- and welfare-related youth 
programmes, and the costs to the State if these programmes were not available? The 
assessment was undertaken on the assumption that annual funding to these programmes 
remains constant over the next 10 years. 
Indecon estimates that the State will benefit by saving costs to the value of €2 billion for an 
€992 million investment over the next 10 years; benefits will exceed projected costs by a 
factor of 2.2. The projected €992 million investment is based on the assumption that the 2011 
funding streams (total receipts of almost €79 million) are maintained and considering the 
relevant adjustments when undertaking such an assessment. 
ASSESSMENT OF THE 
 FO EULAV CIMONOCE 
YOUTH WORK
Prepared by Indecon  
 International Economic Consultants
National Youth Council of Ireland
Improving people’s health through research and information
drugnet 
Ireland
Alcohol and Drug Research Newsletter
Issue 45 
Spring 2013
contents
In respect of the economic value of health-
related youth work programmes which include 
the Young Person’s Facilities and Services 
Fund (YPFSF) and HSE and local drugs task 
force funding streams, Indecon compared the 
cost of funding such programmes with the 
estimated cost to the State if these services 
were unavailable at the youth work organisation 
level. Funding provided through the YPFSF 
and local drugs task forces, with additional 
health-promotion-related funding provided by 
the HSE, is distributed to organisations whose 
programme are directed towards young people 
who are at risk of substance abuse and the 
associated adverse health-related impacts. If 
2011 funding levels were to be maintained, 
the estimated cost of health-related funding to 
the youth sector over a 10-year period would 
be €420.5 million. Indecon assumes that in the 
absence of this funding an estimated 4% of 
beneficiaries of these youth-work programmes 
would have to receive treatment for substance 
abuse in adolescent treatment centres at a cost 
to the State of €60.6 million annually, or €509.9 
million in present value terms over a 10-year 
period; maintaining health-related funding at 
2011 levels would save the State an estimated 
€89.5 million over the projected 10-year period. 
Qualitative evidence on the impacts of youth 
work in Ireland 
The views of over 40 organisations working in 
the youth sector were sought in relation to the 
levels of significance they attach to their work 
with youth. According to the report (p.19), ‘a 
large majority of organisations in the sector 
attach very significant or significant levels of 
importance to the following aspects of youth 
work: 
 ■ helping young people to gain practical skills,
 ■ helping young people to gain education and 
training qualifications,
 ■ helping to reduce costs associated with 
crime and anti-social behaviour,
 ■ helping to reduce health and social care 
costs associated with substance misuse,
 ■ helping to expand labour market and other 
economic opportunities for young people, 
and
 ■ Helping to promote equal economic 
opportunity between women and men.’
The relative significance of these particular 
aspects of youth work, as reported by 
organisations involved in the youth sector  
in Ireland, reflects to a large degree the 
important aspects of youth work reported in  
the international literature and summarised  
in this report. 
Conclusion
According to Indecon, 
The results of this cost-benefit analysis 
suggest that the public funding provided by 
the State for youth work services represents 
value for money. This reflects in particular 
the benefits of targeted programmes in the 
areas of justice, health and welfare, which 
address the needs of young people in a 
pre-emptive and holistic manner, compared 
to a scenario where the absence of these 
supports is likely to mean that the State 
would face substantially greater costs over 
the longer term. (p.119)
This report is timely and instructive. It is timely 
in that it presents a strong case for maintaining 
current levels of funding to the youth work 
sector, despite the many competing claims 
for State funding from the public purse. It is 
instructive in that it signals the changing nature 
of youth work in Ireland; it points to the large 
numbers of young people aged 10–24 who rely 
on the services of the youth sector, an estimated 
43% of this age cohort nationally; it points 
to the challenging work undertaken by youth 
workers to prevent young people becoming 
embedded in a life of substance abuse and 
crime. 
Finally, the report spells out the economic and 
socially disadvantaged conditions that underpin 
the lives of over half of all young people 
attending youth work services (based on 2011 
figures); this is a reminder that the rationale 
for targeting funding to the most at-risk 
communities which underpinned the rationale 
and emergence of the YPFSF and the local 
drugs task forces remains relevant today. Taken 
together, these components which make up the 
nature of youth work in contemporary Ireland 
signal a clear need for maintaining current 
funding levels on the basis that this money 
and the work of this sector is an investment 
in the social capital of young people and the 
communities in which they live. 
(Martin Keane)
1. Indecon International Economic Consultants 
(2012) Assessment of the economic value of 
youth work. Report prepared for the National 
Youth Council. Dublin: National Youth Council 
of Ireland. www.drugsandalcohol.ie/19045
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structures continues
On 18 December 2012 Alex White TD, Minister of State 
with responsibility for the National Drugs Strategy (NDS), 
published the Department of Health’s 15 recommendations 
with regard to the first of the terms of reference for 
the review of drugs task forces (DTFs), i.e. the role and 
composition of DTFs and the national structures under 
which they operate.1 The report on this first stage of the 
review proposes three main changes.
1. Rename the drugs task forces ‘drug and alcohol task 
forces’ (DATF). Their terms of reference are to implement 
the NDS at regional and local level and to support and 
strengthen community-based responses. As previously, 
this role includes maintaining an overview of regional 
and local developments, promoting strategies and 
monitoring, evaluating and assessing the impact of 
funded projects.
2. Reconstitute the Drug Advisory Committee as a National 
Co-Ordinating Committee for Drug and Alcohol Task 
Forces (NCC–DATF). Its terms of reference are to drive 
implementation of the NDS at local and regional level. 
3. Reduce the number of task forces from 24 to 19 by 
merging some task forces and expanding the boundaries 
of others.
The governance framework within which these new 
structures are to operate has yet to be announced. For 
example:
Alcohol –The newly-named task forces will have responsibility 
for alcohol as well as drugs. Which individuals or bodies at 
national level are to have responsibility for alcohol policy and 
how will the DATFs be accountable to these entities? 
Organigram – A large number of individuals and bodies 
have responsibility for different aspects of drug and alcohol 
policy. Previous policy documents have explained in detail, 
and provided organigrams of, the relationships between 
these different entities.2 While it may be surmised that some 
of the relationships have not changed in any material way, 
clarification is needed in some areas. For example:
How are drug and alcohol policies being handled at cabinet 
level? 
How will the new NCC–DATF relate to the Minister of 
State and to the Oversight Forum for Drugs (OFD)? How 
will it relate to the Drugs Policy and Drugs Programmes 
units in the Department of Health? Which entities will have 
responsibility for which decisions? Recommendations 1 and 
7 suggest that the NCC–DATF will have a mainly advisory 
role, while Recommendations 2, 8 and 9 suggest that 
officials in the Department of Health will have responsibility 
for performance, financial control and governance. 
Finally, the status of the National Advisory Committee on 
Drugs (NACD) remains to be clarified. Under the 2009–2016 
NDS, the NACD was subsumed under the Office of the 
Minister for Drugs (OMD). With the abolition of the OMD in 
early 2011, where does the NACD now fit? 
Task force areas – Recommendation 11 of the report states 
that local members of the Oireachtas and members of 
relevant local authorities should have ‘automatic entitlement’ 
to sit on DATFs. A quick look at a recent IPA Administration 
Yearbook suggests that some 860 elected representatives 
(including members of the Oireachtas and of county, city, 
borough and town councils) will be entitled to sit on one of 
the 19 DATFs – an average of 45 public representatives per 
DATF. Clarification is needed as to who precisely will have 
this entitlement and how the efficiency and effectiveness of 
the DATFs will be maintained.
Funding and governance to be addressed next
The second and third terms of reference specified for the 
review – streamlining the funding arrangements for drugs 
projects in DTF areas, and overhauling the accountability 
and reporting arrangements for drugs projects funded by 
DTFs – have yet to be delivered on. The December 2012 
report states that Minister White has requested officials to 
bring forward proposals with regard to these matters. He has 
also invited stakeholders ‘who may have further comments 
to make on this issue to submit their views to his office at 
the earliest opportunity’. No deadline for these submissions 
is specified.
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Mid-term review of the NDS?
Arguably, the review of DTFs would have benefited from 
being undertaken within the context of an overall review 
of the current NDS, which passed its midway point in 
2012. The mid-term review of the 2001–2008 national 
drugs strategy resulted in significant adjustments.3 It 
seems reasonable to believe that a review of developments 
between 2009 and 2012, both in Ireland’s wider socio-
economic environment and in the drugs area, would also 
lead to changes that would enhance the NDS. 
Action 57 of the 2009–2016 NDS established an Office 
of the Minister for Drugs (OMD), which was abolished in 
March 2011. It marked a significant departure in how drug 
policy was co-ordinated.4 It is regrettable that no review 
of this OMD, in place for some 18 months, has ever been 
published. The Steering Group that developed the OMD 
acknowledged that the previous national co-ordination 
structures had ‘stimulated and promoted inter-agency 
working in a difficult cross-cutting policy and service area’, 
but that there were ‘capacity and structural limitations’. The 
Steering Group argued that the OMD model would facilitate 
‘greater coherency in policy-making and service delivery … 
[and] provide a more cohesive and integrated framework 
that promotes closer co-operation and accountability 
between the different players, as well as greater transparency 
for expenditure’.5 
(Brigid Pike)
1. Department of Health (2012) Report on the review of drugs 
task forces and the national structures under which they 
operate. Dublin: Department of Health.  
www.drugsandalcohol.ie/19054 
2. See Working Group on Drugs Rehabilitation (2007) 
National drugs strategy 2001–2008: rehabilitation. Dublin: 
Department of Community, Rural and Gaeltacht Affairs 
www.drugsandalcohol.ie/6267/, and Department of 
Community, Rural and Gaeltacht Affairs (2009)  
National drugs strategy (interim) 2009–2016. Dublin: 
Department of Community, Rural and Gaeltacht Affairs.  
www.drugsandalcohol.ie/12388/ 
3. Steering Group for the Mid-term Review of the National 
Drugs Strategy (2005) Report of the steering group on the 
mid-term review of the national drugs strategy 2001–2008. 
Dublin: Department of Community, Rural and Gaeltacht 
Affairs. www.drugsandalcohol.ie/3887/ 
4. For a full discussion, see Pike B (2009) Taoiseach launches 
new national drugs strategy: Co-ordination pillar. Drugnet 
Ireland, (31): 6–8. www.drugsandalcohol.ie/12450/ 
5. Department of Community, Rural and Gaeltacht Affairs 
(2009) National drugs strategy (interim) 2009–2016. Dublin: 
Department of Community, Rural and Gaeltacht Affairs 
(paras 6.44–6.45). www.drugsandalcohol.ie/12388/
HSE targets for drug-related services  
in 2013 
Each year the Health Service Executive (HSE) publishes a 
‘national service plan’ (NSP). The plan sets out the type 
and volume of services to be delivered during the year. In 
2013, according to the newly released NSP,1 service activity 
volumes in relation to drug-related treatment are expected 
to be similar to last year’s targets (see following table). A 
new performance indicator (PI), monitoring the number of 
unique individuals attending a pharmacy needle exchange, 
has been included. 
NSP 2013 is a much shorter document than previous years’ 
plans.2 Deliverables, including priorities, key actions and 
measures, are not included. Moreover, there is no discussion 
of the past year’s performance vis-à-vis that expected in the 
coming year, for instance, how the reported 19% shortfall 
in the delivery of treatment to substance misusers over the 
age of 18 within one month of assessment in 2012 will be 
corrected in 2013, or how the roll-out of pharmacy-based 
needle exchanges will be speeded up in the current year.
Broader challenges
The HSE’s drug-related services may be expected to be 
influenced by the two broader challenges outlined in NSP 
2013. First, in November 2012 the Minister for Health 
published Future health, the framework for ‘the most radical 
reform of our health services in the history of the state’.3 The 
core of this reform is a single-tier health service, supported 
by universal health insurance (UHI). The government is 
seeking innovative ways of care delivery and in particular 
integrated care pathways, to be achieved under the most 
stringent fiscal constraints experienced for decades. 
Expected 
activity 2012
Projected 
outturn 2012
Expected 
activity 2013
Methadone treatment 
Number of clients in methadone treatment (outside prisons)  
(monthly target) 8,640 8,855 8,650
Substance misuse 
Number of substance misusers (aged over 18 years) for whom treatment 
has commenced within one calendar month following assessment 1,260 1,025 1,260
Needle exchange 
Number of pharmacies recruited to provide needle exchange programme
45 in Q1
65 in Q3 65 130
Number of unique individuals attending pharmacy needle exchange New PI 2013 New PI 2013 200 in Q1  
250 in Q2  
300 in Q3  
400 in Q4
Source: NSP 2013, p. 24
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Thus, the HSE will proceed with ‘business-as-usual’ in 
2013, while also implementing structural reforms including 
changes to the way that hospital services are funded and 
managed, disaggregating childcare services from the HSE 
and establishing a child and family support agency, setting 
up a new directorate structure, establishing a patient safety 
agency, and ensuring that social care services including 
mental health, disability and primary care are fit for purpose. 
A second key priority for drug-related treatment services 
will be to ensure that financial and service performance 
is reported on and managed in a timely and proactive 
manner. Building on the work of recent years, the 2013 
accountability framework is intended to ensure that 
performance is measured against agreed plans that specify 
access targets, service quality and volumes. These plans will 
be monitored through a range of scorecard metrics. Service 
managers will be held to account and under-performance 
will be addressed.
The financial framework is intended to ensure that all areas 
of the health care system have budgets that are achievable, 
while also delivering the savings necessary. For the first 
time, the allocations outlined in the plan are based on the 
projected spend rather than on historic budgets, with a view 
to ensuring sustainable budgets. 
(Brigid Pike)
1. Health Service Executive (2013) Health Service Executive 
national service plan 2013. Dublin: Health Service Executive. 
www.drugsandalcohol.ie/19102/ 
2. See for example Pike B (2012) HSE plans to maximise 
efficiencies. Drugnet Ireland, (41): 10–12.  
www.drugsandalcohol.ie/17273/ 
3. Department of Health (2012) Future health: a strategic 
framework for reform of the health service 2012–2015. Dublin: 
Department of Health. www.drugsandalcohol.ie/18790/
Fourteenth annual Service of 
Commemoration and Hope 
On Friday 1 February, the Family Support Network (FSN) 
held its fourteenth annual Service of Commemoration and 
Hope, entitled ‘Our Children, Our Family’, in remembrance 
of loved ones lost to substance misuse and related causes 
and to publicly support families living with the devastation 
that substance misuse causes.
The service in Our Lady of Lourdes Church, Sean McDermott 
Street, was attended by Mr Alex White TD, Minister of 
State, Commandant Michael Treacy, aide de camp to the 
Taoiseach, Assistant Garda Commissioner John Twomey, 
Counsellor Ray McAdam representing the Lord Mayor of 
Dublin, Bishop Eamonn Walsh, Fr Tim Wrenn and other 
religious representatives, as well as family members, friends 
and representatives from family support groups throughout 
Ireland, and many people working in this area. 
In her address to the gathering, Sadie Grace of the FSN 
spoke about the impact of substance misuse on children 
and the family. Children who have been affected by parental 
substance misuse often have to be cared for by grandparents 
and other family members. She stressed the importance 
of providing services for young people. In response to this 
the FSN has developed a sibling support programme (for 
those aged 12 to 18 years). Sadie also spoke about the 
stigma of parents being abused by their children, and said 
that the FSN hope to hold a seminar on the topic this year. 
The FSN will continue to roll out their training programme 
‘Responding to Intimidation Policy’ in different parts of 
the country. Finally, Sadie spoke about the difficulty of 
maintaining services in light of recent cuts to the network’s 
budget and urged that support of family members living 
with substance misuse be prioritised. 
Attending this service for the first time, Minister White said 
he recognised what an important event it was for family 
members, one that allowed them to mourn openly, but 
also to celebrate the lives of those who had been lost to 
substance misuse. He felt it also provided an opportunity 
to look forward and build hope. He acknowledged that it 
was all too often the children who were affected by drug 
problems in the family. Minister White stated that his 
department will continue to provide funding to support the 
work of the FSN. He also spoke about the problem of alcohol 
misuse and said that his department would be working on 
that issue in the coming weeks. 
There were a number of personal pieces included, always a 
central part of the service. Gordon Jeyes, National Director 
of Children and Family Services, recited poetry by Mervyn 
Peake. Fr Edmond Grace gave a reflection. Mr Brendan 
Doyle, a member of the Wexford FSG, gave a moving 
testimony about the experience of his family. Ms Michelle 
Kavanagh (on behalf of UISCE and SAOL project) recited 
her own poem about recovery. Mr Reginald Oko-Flex Inya 
of the New Communities Partnership said a prayer. Music 
was provided by the soprano Nickola Hendy and St Mary’s 
Youth Club Drama Group. In keeping with the theme ‘Our 
Children, Our Family’, the girls of the Francesca Arkins 
Dance and Stage Academy performed a dance recital to a 
musical accompaniment at the beginning of the service, 
which was very well received. 
The service was attended by many members of family 
support groups from all over the country, including Northern 
Ireland, reflecting the growth and success of the FSN.
(Suzi Lyons) 
Contact the Family Support Network at 16 Talbot Street, 
Dublin 1. Tel: 01 836 5168; email: info@fsn.ie;  
web: www.fsn.ie
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On 10 December 2012 the UK Home Affairs Select 
Committee published its report on the illicit drugs issue.1 
It was the first such parliamentary review of drug policy 
as a whole since 2002. It reveals a shift in opinion among 
some key policy makers, away from an enforcement-led 
strategy towards a more nuanced drug policy. The key 
recommendations are listed below.
Drug education in schools 
‘The evidence suggests that early intervention should be an 
integral part of any policy which is to be effective in breaking 
the cycle of drug dependency. We recommend that the next 
version of the drugs strategy contain a clear commitment 
to an effective drugs education and prevention programme, 
including behaviour-based interventions.’ (para. 75)
Residential rehabilitation treatment
‘Different treatment régimes will work for different patients. 
It is clear that, for some people, residential rehabilitation is 
the most effective treatment, backed by proper aftercare 
in the community. We recommend that the Government 
expand the provision of residential rehabilitation places. 
In addition, we recommend the Government review the 
guidance for referrals to residential rehabilitation so that 
inappropriate referrals are minimised.’ (para. 94)
‘Outcomes which range from 60% of patients overcoming 
their dependence to just 20% suggest that the quality of 
provision is very variable. We recommend that, in line with 
the publication of certain outcome statistics for National 
Health Service providers, publicly-funded residential 
rehabilitation providers should be required to publish 
detailed outcome statistics so that patients and clinicians can 
make better-informed choices of provider.’ (para. 96)
Opioid substitution treatment 
‘Policy makers should … continue to keep sight of a 
greater emphasis on buprenorphine relative to methadone 
prescription to lead to better patient and societal outcomes.’ 
(para. 100) 
Prescription drug dependence 
‘Prescription drugs are becoming more widely available, 
through diversion of prescriptions and unregulated sales via 
the internet. Having seen first-hand the scale and impact 
of prescription drug use in Florida, we recommend that 
the Government publish an action plan of how it intends 
to deal with this particular issue as part of the next version 
of the drug strategy to prevent the situation here in the UK 
deteriorating further.’ (para. 122)
Royal Commission on how to reduce drug-related harm
‘Our predecessor Committee’s recommendation for an 
independent assessment of the Misuse of Drugs Act 1971 
was rejected on the basis that it gives effect to the UK’s 
international obligations in this area. That is not, in our view, 
a compelling reason for refusing to review our own domestic 
legislative framework, particularly given the growing concern 
about the current international regime in many producer 
nations. … We are not suggesting that the UK should act 
unilaterally in these matters, but our Government’s position 
must be informed by a thorough understanding of the 
global situation and possible alternative policies.’ 
‘… We recommend the establishment of a Royal 
Commission to consider the best ways of reducing the harm 
caused by drugs in an increasingly globalised world. In order 
to avoid an overly long, overly expensive review process, we 
recommend that such a commission be set up immediately 
and be required to report in 2015. (paras 131 and 132) 
New psychoactive 
substances 
‘The market in new 
psychoactive drugs 
is changing quickly, 
too quickly for the 
current system of 
temporary banning 
orders to keep up. 
… We recommend 
that the Government 
issue guidance to 
Local Authority 
trading standards 
departments, citizens 
advice bureaux and 
other interested parties on the action which might be taken 
under existing trading standards and consumer protection 
legislation to tackle the sale of these untested substances.’ 
(para. 170) 
Drugs in prisons
‘We recommend that the Ministry of Justice introduce 
mandatory drug-testing for all prisoners arriving at and 
leaving prison whether on conviction, transfer or release. 
Tests should be carried out for both illegal and prescription 
drugs. This should be in addition to the existing random 
testing regime, the principal purpose of which is deterrence. 
The information obtained from such a test would be very 
valuable in evaluating the effectiveness of the current 
systems in place and identifying those prisons which have a 
serious problem.’ (para. 211) 
Evidence-based policy
‘We were impressed by what we saw of the Portuguese 
depenalised system. It had clearly reduced public concern 
about drug use in that country, and was supported by all 
political parties and the police. … Following the legalisation 
of marijuana in the states of Washington and Colorado and 
the proposed state monopoly of cannabis production and 
sale in Uruguay, we recommend that the Government fund 
a detailed research project to monitor the effects of each 
legalisation system to measure the effectiveness of each and 
the overall costs and benefits of cannabis legalisation.’ (paras 
243 and 248) 
‘We recommend the Government allocate ring fenced 
funding to drugs policy research going forward.’ (para. 257) 
Need for debate
‘We recommend that the Government instigate a public 
debate on all of the alternatives to the current drugs policy, 
as part of the proposed Royal Commission.’ (para. 260) 
Following the release of the report, Prime Minister David 
Cameron rejected the recommendation with regard to a 
Royal Commission. In contrast, Deputy Prime Minister Nick 
Clegg committed his party to pledging a major review 
of how to tackle the drug problem in its 2015 election 
manifesto. 
(Brigid Pike)
1. Home Affairs Committee (2012) Drugs: breaking the 
cycle. Ninth report of House of Commons Home Affairs 
Committee. London: The Stationery Office.  
www.drugsandalcohol.ie/18933/ 
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thinking’
In December 2012 the Council of the European Union 
adopted a new drugs strategy for the next eight years 
(2013–2020).1 As before, the new strategy identifies 
priorities in five thematic areas – co-ordination, demand 
reduction, supply reduction, international co-operation, and 
research, evaluation and information. It will be implemented 
by means of two consecutive four-year action plans. 
The new strategy reveals new thinking on some aspects of 
drug policy. While drug policy lies within the competence of 
individual member states, it may be expected that the new 
thinking will trickle down to member states’ drug policies. 
Evidence-based policy 
The word ‘evidence’ did not occur once in the 2005–2012 
drugs strategy. It appears 13 times in the new strategy. 
While the former strategy called for a ‘balanced, integrated 
approach to the drugs problem’, the new strategy calls for a 
‘balanced and integrated and evidence-based approach to 
the drugs phenomenon’. 
Under the supply reduction pillar, priority is to be given to 
expanding and improving the knowledge base with regard 
to supply reduction and to developing accurate indicators of 
progress. Under the demand reduction pillar, while the Council 
acknowledged that there had been some success in promoting 
evidence-based approaches,2 the new strategy prioritises 
the need for greater uniformity across all member states in 
implementing harm reduction and treatment measures. 
Not all drug use is problematic
The term ‘drug problem’, which was used throughout the 
2004–2012 drugs strategy, has been replaced by the more 
neutral term ‘drug phenomenon’, implying that not all drug 
use is viewed as problematic. MacGregor (2012) comments 
that the distinction between abstinence and addiction, 
which implies all drug use is ‘problematic’, is not useful. She 
suggests that the way forward is ‘to develop more nuanced 
responses to the range of different substances [including 
alcohol and tobacco] available, which are used in different 
ways by different people in different situations and at 
different times.’3
Human rights 
Human rights is more strongly emphasised in the new 
strategy. Although referred to in the previous strategy, 
the new strategy names the specific international human 
rights agreements that underpin the EU’s drug policy – the 
Universal Declaration on Human Rights, the European 
Convention on Human Rights and the EU Charter of 
Fundamental Rights. 
Policy coherence 
The new EU drugs strategy mentions the concept ‘policy 
coherence’ in relation to ensuring coherence between 
drug demand reduction policies and broader health, 
social and justice policies, and between the internal and 
external aspects of the EU’s drugs policies and responses 
towards third countries in the field of drugs. However, it 
has not extended the concept to include licit substances 
such as alcohol, tobacco or prescribed or over-the-counter 
medicines or to include other addictive behaviours such as 
gambling or Internet usage.
The Council of Europe’s Pompidou Group has gone to 
this next stage. Its guidance to policy makers on coherent 
policies for licit and illicit drugs states:4
The fact that often substance abuse and other addictions 
are interrelated calls for coherence and consistency 
between policies dealing with licit and illicit drugs as 
well as those dealing with other forms of addiction and 
dependency, notably addiction to medicines, gambling 
or Internet usage. As a result, public health and 
increasingly ‘well-being’ are becoming the overarching 
starting point for policy approaches that embrace both 
licit and illicit substances ...’ (para. 3.5)
While not using the terms ‘policy coherence’, the authors 
of the independent assessment of the 2005–2012 EU 
drugs strategy noted the emergence of the concept.5 
They observed that drugs supply was increasingly being 
considered within the broader context of EU policy on 
organised crime and security, but that this ‘horizontal 
integration’ had not taken place on the demand side. 
They further noted that there was a desire among 
many stakeholders to consider drug use in such a policy 
framework, including both licit and illicit substances and 
other addictive behaviours. 
Co-ordination
According to paragraph 23 of the new EU drugs strategy, 
co-ordination has two objectives: ‘to ensure synergies, 
communication and an effective exchange of information 
and views in support of the policy objectives, while at the 
same time encouraging an active political discourse and 
analysis of developments and challenges in the field of drugs 
at EU and international levels’. The participation of NGOs, 
young people, drug users and the EU Civil Society Forum 
on Drugs in the development of drug policies are particular 
priorities in terms of co-ordination.
Governance
Whereas monitoring and reporting on the implementation 
of the new EU drugs strategy and action plan formerly 
rested with the European Commission, these tasks are now 
the responsibility of the holders of the EU presidency. Thus, 
Ireland, which has the presidency of the EU from January to 
June 2013, is responsible for drawing up the first four-year 
action plan to accompany the new strategy. 
(Brigid Pike)
1. Council of the European Union (2012, 11 December) 
EU drugs strategy (2013–2020). 17547/12, JAI 901 
CORDROGUE 101 SAN 324 JAIEX 124.  
www.drugsandalcohol.ie/19034. The preliminary 
deliberations on the shape of the new EU drugs  
strategy were described in Pike B (2012) EU drugs  
policy – what next? Drugnet Ireland, (43): 6.  
Available at www.drugsandalcohol.ie/18456 
2. Council of the European Union (25 May 2012) Draft Council 
conclusions on the new EU drugs strategy. 10231/12, 
CORDROGUE 37 SAN 121 ENFOPOL 145 RELEX 455.  
http://register.consilium.europa.eu/pdf/en/12/st10/st10231.
en12.pdf 
3. MacGregor S (2012) Do we need an EU drugs strategy? 
Drugs: education, prevention and policy, 19 (6): 429–435. 
4. Pompidou Group (2011) Policy paper providing guidance  
to policy makers for developing coherent policies for licit  
and illicit drugs. Adopted at the 69th meeting of  
permanent correspondents, P–PG (2011) 4 final 14.  
www.drugsandalcohol.ie/17318; R Muscat, B Pike and 
members of the Coherent Policy Expert Group (2012) 
Reflections on the concept of coherency for a policy on 
psychoactive substances and beyond. Strasbourg: Council  
of Europe Publishing. 
5. Culley DM, Skoupy J, Rubin J, Hoorens S, Disley E and 
Rabinovich L (2012) Assessment of the implementation of the 
EU drugs strategy 2005–2012 and its action plans. Technical 
Report prepared for European Commission Directorate 
General for Justice. Santa Monica, CA: RAND Corporation. 
www.drugsandalcohol.ie/17312 
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An EU drug markets 
report, jointly 
published by the 
EMCDDA and 
Europol, is the first 
comprehensive 
overview of illicit 
drug markets in the 
European Union.1 It 
covers issues such 
as drug production, 
consumer markets, 
trafficking, organised 
crime involvement 
and policy 
responses, along 
with a review of the 
markets for heroin, 
cocaine, cannabis, 
amphetamine, methamphetamine, ecstasy and new 
psychoactive substances. It concludes with concrete action 
points for the areas where the current EU response to the 
drug market and its consequent harms may be improved. 
The report highlights a number of factors relevant to the 
Irish illicit drugs market, and Ireland’s response to the 
‘head shop’ phenomenon, an issue of growing concern 
throughout Europe.
A comparative study of this nature can be useful, even in 
terms of trying to understand national developments in 
drug markets. For example, in late 2011, information was 
gathered in an attempt to understand anecdotal reports of a 
reduction in the supply of heroin in Europe: ‘Evidence of this 
phenomenon was collected between November 2010 and 
March 2011 from Bulgaria, Ireland, Hungary, Slovakia, the 
United Kingdom, Switzerland and some regions in Russia, 
whereas heroin remained available, with possible increases 
in purity, in Belgium and France’ (p.30). Although the causes 
of these developments remain unclear – they may relate to a 
shift in demand towards alternative drugs, such as fentanyl, 
or the possible disruption of heroin supply routes through 
Turkey owing to law enforcement efforts – research of this 
nature at an international level can help explain national 
trends.2
With regard to cocaine consumption among young adults 
in Europe, Ireland is included in a list of relatively high-
prevalence countries, which also includes Spain, the UK, Italy 
and Denmark: ‘These five countries alone account for 1.7 
million (or 62%) of the estimated 2.7 million users “in the 
last 12 months” in the 15–34 age group, with prevalence 
levels of between 2.6% and 4.4%. The European prevalence 
rate for “last 12 months” use amongst young adults stands 
at 2.1%’ (p.42). 
Ireland is also among a number of countries that have 
experienced increases in the domestic cultivation of herbal 
cannabis in the last five years. The others are Austria, 
Belgium, the Czech Republic, Denmark, Finland, Germany, 
Hungary, Poland, the Netherlands, Norway, Slovakia, 
Sweden and the UK (p.59). Using drug seizure size as 
an indicator, the report also provides a useful picture of 
cannabis resin supply routes into and throughout Europe. 
It is reported that Ireland is a transit point for cannabis en 
route to the UK and onwards into mainland Europe: 
Average seizure sizes greater than 1kg suggest that 
Ireland is…an entry point for Moroccan resin into 
Europe. Resin seizures represent about 15% of estimated 
national consumption; it is likely that some of the 
resin entering Ireland eventually ends up in the United 
Kingdom, where the market for resin, although smaller 
than the market for herb, is still rather large, estimated 
to be about seven times the size of the Irish market. 
Seizures in the United Kingdom are on average smaller 
than in Ireland (under 1kg) and represent one-third of 
estimated national demand… (p.62)
The report also considers the involvement of organised 
crime groups (OCGs) in drug production and trafficking. 
With regard to herbal cannabis it is reported that 
‘Vietnamese OCGs have become prominent in the indoor 
cultivation of cannabis in many EU countries, particularly 
Belgium, the Czech Republic, Germany, Ireland, France, 
Hungary, the Netherlands, Poland, Slovakia and the United 
Kingdom’(p.64). These OCGs are described as ‘hierarchical 
in structure’, incorporating a range of specialised personnel, 
including ‘electricians, plumbers and managers of cultivation 
facilities’ (p.64). The report also alludes to the social factors 
that can lead to people becoming involved with such illegal 
activities. In relation to herbal cannabis, ‘Gardeners tending 
the plants are often illegal migrants working to pay off their 
passage’ (p.64).
Synthetic drugs are produced mainly in Belgium and the 
Netherlands. However, police intelligence suggests ‘the 
growing prominence of Polish and Lithuanian OCGs in 
trafficking drugs obtained in the Netherlands to various 
Nordic and Baltic States, Ireland and the United Kingdom’ 
(p.78).
The report also looks at the increasing importance of 
the internet as a source of supply of new psychoactive 
substances and ‘legal highs’, an issue that has featured on 
the political agenda in Ireland.3 EMCDDA data show that the 
number of online shops offering these substances increased 
from 170 in January 2010 to 693 in January 2012 (p.106). A 
recent Eurobarometer survey referred to in the report found 
that, among 15–24-year-olds, ‘lifetime use of “legal highs” 
in most Member States was 5% or less’, whereas ‘use in the 
United Kingdom, Latvia, Poland and Ireland was 8%, 9%, 
9% and 16% respectively’ (p.106). The high rate in Ireland 
can be traced to the significant number of ‘head shops’ 
operating in this country in the years covered by this report.
The report also describes the legislative approaches adopted 
in different member states, particularly in response to 
the growing number of new drugs. While some member 
states, such as Ireland and the UK, have adopted a ‘generic’ 
approach, whereby families of substances are scheduled 
on the basis of their chemical make-up, in other countries 
‘legislation covers a wider range of derivatives of controlled 
drugs with similar structures or effects’, known as an 
‘analogue’ approach (p.113).
According to the report: ‘The rapid spread of new drugs is 
prompting some Member States to rethink their response 
to the problem.’ Recently enacted legislation in Ireland, in 
the form of the Criminal Justice (Psychoactive Substances) 
Act 2010, and similar legislation introduced in Poland, are 
mentioned in this regard. In each case the new law defines 
proscribed drugs in functional terms rather than in terms 
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experiences of an Irish juror 
My journey as a jury member began when I was in Transition 
Year in secondary school. I got involved with a peer drug 
education programme called 421.1 Set up in 2004 by 
Mel Bay and Susan Barnes of Ossory Youth, Kilkenny, the 
programme consisted of 12 peer educators including 11 
girls and myself. We received training in how to create 
and deliver a drug education class to a group of first-year 
students once a week over a six-week period.
In 2006 Mel and Susan decided to enter the 421 
programme for the 2006 European Drug Prevention Prize. 
The Pompidou Group secretariat invited a representative 
of 421 to a European Drug Forum in Vilnius, Lithuania. 
I was the peer educator lucky enough to represent the 
421 programme at the Forum, during which I got the 
opportunity to meet with other people who work in drug 
prevention around Europe and learn about the work they 
do. Our programme was one of two winners of the prize in 
2006; the other winner was a project from Norway. Three 
years later the Pompidou Group secretariat was recruiting 
young people to serve on the jury via a network of youth 
associations involved in drug prevention activities. Mel Bay 
was invited to nominate someone and he suggested that 
I should apply. My application was successful and a few 
months later I joined the jury for the 2010 and 2012 prizes. 
For each prize, the jury met twice. At a preparatory meeting 
in Strasbourg, we discussed the rules and procedures, 
the selection criteria by which we would evaluate the 
applications and the information which should be provided 
in the application form. We were assisted by three experts 
in the field of drug prevention whose role was to answer 
any queries and to offer us advice if we needed it. When the 
official call for applications for the prize was issued, all the 
required information was publicised and sent to networks 
concerned with drug prevention and youth activities. 
Following the closing date for applications for the prize, the 
jury held a selection meeting to discuss and evaluate the 
applications, and to decide on the shortlisted projects. 
In 2012, at the selection meeting, we had 83 applications 
from 24 countries to consider. The three winning projects 
were selected from a shortlist. We chose those that we 
considered had active youth participation and which were 
the most innovative in their drug prevention activities. 
The winning projects came from Lebanon, Germany and 
Spain. Ten other shortlisted projects were nominated for 
their noteworthy work in drug prevention with the active 
involvement of young people. 
EU drug markets (continued)
of their chemistry: ‘This required careful legal definitions 
of such substances. Briefly, the Irish law defines them as 
psychoactive substances not specifically controlled under 
existing legislation. The Polish law refers to “substitute 
drugs”, defined as a substance or plant used instead of, or 
for the same purposes as, a controlled drug, and whose 
manufacture or placing on the market is not regulated by 
separate provisions’ (p.113).
The report concludes by highlighting a number of action 
points that need to be adopted across the EU in response 
to the various issues raised. These cover such areas as 
organised crime; the global nature of the drugs market and 
the engagement with producer and transit countries; the 
importance of the internet; as well as specific actions in 
relation to cannabis, heroin, cocaine, synthetic drugs and 
new psychoactive drugs. Finally, the report highlights the 
importance of developing high-quality indicators of drug 
supply, further integrating forensic science information and 
enhancing the evidence base through the identification of 
research needs and the promotion of cross-national and 
multidisciplinary studies. 
(Johnny Connolly)
1. European Monitoring Centre for Drugs and Drug Addiction, 
Europol (2013) EU drug markets report: a strategic analysis. 
Luxembourg: Publications Office of the European Union. 
www.drugsandalcohol.ie/19227
2. For a discussion of the heroin drought in Ireland see Stokes 
S (2012) Quantitative evidence of a heroin drought. Drugnet 
Ireland, (40): 21–23. www.drugsandalcohol.ie/16882
3. Connolly J (2012) Impact of legislation to control head 
shops. Drugnet Ireland, (40): 29.  
www.drugsandalcohol.ie/16890
The European Drug Prevention Prize was launched by the Pompidou Group of 
the Council of Europe in 2004. It is awarded every two years to innovative drug 
prevention projects led by young people for young people. The objective is to 
recognise the importance of active youth participation in creating a better and 
healthier environment for all communities in Europe. 
Participation has expanded dramatically, from 18 countries submitting 44 projects 
in 2004 to 24 countries submitting 83 projects in 2012, the most recent year in 
which the prize was awarded. Ireland has entered projects over the years, and was 
a winner in 2006 with a project entitled 421.1 
The jury for the European Drug Prevention Prize comprises six young people, aged between 18 and 23. The jury is 
supported by an advisory group of three experts. The young jurors autonomously select the three prize-winners from 
among the applications submitted. The three projects which they consider to be the most innovative regarding drug 
prevention and the active involvement of young people from the setting-up to the running of the project are awarded the 
prize, which comprises a trophy, a diploma and €5,000 in prize money. 
A young Irish woman, Rachel Walsh, was a member of the jury for the 2010 and 2012 awards. She describes her 
experiences as a juror.
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The participation of a broad range of countries adds 
considerable value not only to the prize but also to European 
drug prevention as a whole. It is uplifting to see what great 
work is being done by inspirational people in their respective 
countries and regions. We examined and read about many 
worthy and encouraging projects that benefit so many 
people. They all displayed the same hard work, dedication, 
heart and soul. That is why jurors have such a difficult job to 
pick just three winning projects. 
There are many benefits to the projects which win the 
European Drug Prevention Prize; not only from the financial 
aspect but also recognition of their hard work on a European 
level, which in turn can raise media awareness and reach out 
to more people. I hope the prize continues to be supported 
because it is important to recognise and encourage young 
people to stay active and involved in such important work in 
the area of drug prevention and harm reduction. 
According to the programme co-ordinator, Mel Bay, 421 
is still being delivered in a number of schools in Kilkenny 
City and County, but it has been adapted to the particular 
circumstances of schools; for example, in some schools it is 
targeted at young people identified as being involved with 
drug use; in other schools it has broadened out to focus 
on mental health and individual development, which will 
naturally cover drugs education but also issues such as sexual 
health, self-harm and bullying, and is targeted at the whole 
school community. 
I have recently got re-involved with Ossory Youth  
(www.ossoryyouth.com), working with young people and 
hoping to give back to the people that gave me my start in 
drug prevention.
Sadly, my time on the jury of the European Drug 
Prevention Prize has ended. The experience has been 
wonderful. I feel privileged that I have been involved in 
something so worthwhile on a European level. I will keep 
those experiences with me forever – and I hope my drug 
prevention work in the future will be better because of it. 
(Rachel Walsh)
1. See Keane M (2006) Peer drugs education programme in 
Kilkenny wins major European award. Drugnet Ireland, (19): 
10. www.drugsandalcohol.ie/11280/
The next European Drug Prevention Prize will be awarded 
in 2014. The call for applications is due to be issued in 
late 2013. For further information, visit www.coe.int/T/
DG3/Pompidou/Initiatives/PreventionPrize/default_en.asp
Clarification
The article ‘Monitoring centre report reveals latest drug trends in Europe’ in Issue 44 of Drugnet Ireland (Winter 2012) 
contained an incorrect statement in relation to the stimulant drug 4-methylamphetamine (4-MA). We wish to clarify that 
4-methylamphetamine is a controlled drug in Ireland under the Misuse of Drugs Act 1977, using a generic definition of 
phenethylamines.
European Drug Prevention Prize (continued)
National Advisory Committee on Drugs 
and Alcohol 
Minister of State at the Department of Health, Mr Alex White 
TD, has reconstituted the National Advisory Committee on 
Drugs for the period until the end of 2016, in line with the 
timescale of the National Drugs Strategy. The Committee is 
being extended to incorporate alcohol as well as drugs and, 
to reflect this, it will henceforth be known as the National 
Advisory Committee on Drugs and Alcohol. 
The role of the new Committee will be to advise government 
on the prevalence, prevention, treatment, rehabilitation and 
consequences of substance use and misuse in Ireland, based 
on the analysis of research findings and information available 
to it. 
Minister White is pleased that Professor Catherine Comiskey 
has agreed to become the Chairperson of the Committee. 
The Committee comprises representatives from government 
departments and state agencies and from the community 
and voluntary sectors. 
The first meeting of the Committee was held on 18 February 
2013. 
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Update on drug-related deaths and 
deaths among drug users 
National Drug-
Related Deaths Index 
(NDRDI) figures on 
drug-related deaths 
and deaths among 
drug users reported 
in 2010 are now 
available online.1 
The figures in this 
update supersede all 
previously published 
figures. Similarly, 
figures for 2010 will 
be revised when data 
relating to new cases 
becomes available.
In the seven-year 
period 2004–2010 a total of 3,972 deaths by drug poisoning 
and deaths among drug users met the criteria for inclusion 
in the NDRDI database. Of these deaths, 2,364 were due 
to poisoning and 1,608 were due to traumatic or medical 
causes (non-poisoning) (Table 1).
Poisoning deaths in 2010
The annual number of deaths increased from 267 in 2004 to 
388 in 2007, but decreased in subsequent years, to a total 
of 323 in 2010 (Table 1). This appears to reflect a downward 
trend in the number of drug-related deaths in Europe in 
2009 and 2010.2 As in all previous years, males accounted 
for the majority of deaths (74% in 2010). The majority were 
aged between 20 and 44 years; the median age was 40 
years.
Just over half (52%) of all poisoning deaths involved more 
than one substance (polysubstance cases). In 2010 the 
number of deaths in which heroin was implicated decreased 
by 39%, to 70 compared to 115 in 2009. The well-
documented heroin drought in Ireland in December 2010 
and the early part of 2011 may well have been a factor in 
this reduction.3 However, further analysis of the data and 
trends in 2011 deaths need to be considered before the full 
impact of that event can be understood. 
Since 2007 there has been a 70% decrease in the number 
of deaths where cocaine was implicated, with 20 deaths 
in 2010 compared to 66 in 2007. This again reflects a 
downward trend in the number of cocaine-related deaths in 
some European countries.2
Alcohol was involved in 46% of all poisoning deaths in 2010, 
more than any other drug. Benzodiazepines, which include 
diazepam and flurazepam, were the second most common 
drug group implicated in poisoning deaths. 
Non-poisoning deaths in 2010
The number of non-poisoning deaths decreased slightly to 
252 in 2010, compared to 278 in 2009 (Table 1). It was 
possible to categorise 243 of the deaths in 2010 as being 
due either to trauma or to medical causes. 
Figure 1 Non-poisoning deaths among drug users, 
NDRDI 2004–2010 (N=1,523)
Deaths due to trauma
The number of deaths due to trauma decreased to 112 
in 2010, down from 132 in 2009 (Figure 1). The majority 
(68%) of those who died were aged under 39 years. The 
median age was 33 years. As in previous years, the majority 
were male (78% in 2010). The most common causes of 
death due to trauma were hanging and drowning.
Deaths due to medical causes
The number of deaths due to medical causes remained 
stable in 2010. However, the numbers have risen steadily 
over the reporting period, increasing from 55 in 2004 to 
131 in both 2009 and 2010 (Figure 1). The majority (63%) 
of those who died were aged between 30 and 49 years. The 
median age was 43 years. Males accounted for 76% of those 
who died. The most common medical causes of death were 
cardiac events and respiratory problems.
(Suzi Lyons and Simone Walsh)
1. Health Research Board (2013) Drug-related deaths and deaths 
among drug users in Ireland: 2010 figures from the National 
Drug-Related Deaths Index. www.drugsandalcohol.ie/18905
2. European Monitoring Centre for Drugs and Drug Addiction 
(2012) Annual report 2012: the state of the drugs problem in 
Europe. Luxembourg: Publications Office of the European 
Union. www.drugsandalcohol.ie/18783 
3. Stokes S (2011) Quantitative evidence of a heroin drought. 
Drugnet Ireland, (26): 21–23.
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Table 1 Number of deaths, by year, NDRDI 2004 to 2010 (N=3,972)
2004 2005 2006 2007 2008 2009 2010
All deaths 431 501 561 628 624 652 575
Poisoning (n=2,364) 267 300 326 388 386 374 323
Non-poisoning (n=1,608) 164 201 235 240 238 278 252
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Trial of group psychological intervention 
for psychosis with cannabis dependence
There are few proven effective interventions for psychotic 
patients who also have a substance dependency. Among 
those diagnosed with schizophrenia, cannabis is the most 
common substance misused. Research points to the fact that 
cannabis use can be a causal factor in both the development 
of psychotic illness and the severity and duration of 
symptoms. Few studies have identified interventions that 
reduce cannabis use and improve clinical outcomes in 
this population. However, a recent UK study found that a 
psychological intervention could help to reduce substance 
misuse in this group of patients.1 
In light of the limited evidence on effective interventions, 
researchers in Ireland carried out a randomised controlled 
trial comparing a group-based psychological intervention 
with standard care among patients in the early course of 
psychotic illness who were also cannabis dependent.2 The 
primary outcome measure was the extent of cannabis 
misuse and the secondary outcome measures were: positive 
and negative symptoms, depressive symptoms, global 
functioning, insight, attitude to treatment and quality of life. 
Participants were recruited from three different sites in 
Ireland: the DETECT service in South County Dublin/North 
Wicklow; the National Drug Treatment Centre Board in 
Dublin city centre; and Cavan-Monaghan Mental Health 
Service. Participants had either experienced their first 
psychotic episode or were within three years of onset of 
non-affective or affective psychosis. 
Participants were randomly assigned (by computer) to 
one of two groups. One group received a group-based 
psychological intervention (GPI) that integrated cognitive 
behavioural therapy with motivational interviewing, in 
addition to standard care. The other group, the treatment 
as usual (TAU) group, received standard care but not the 
additional group-based psychological intervention. A clinical 
nurse specialist used a range of standardised measures and 
questionnaires to rate the outcome measures at follow up. 
Participants were followed up at three months and at one 
year. 
Of the 88 participants recruited, 59 were randomly allocated 
to the GPI group and 29 were randomly allocated to the 
TAU group. Data were analysed on an intention-to-treat 
basis. Mean lifetime use of cannabis was 9.6 years in the 
GPI group and 7.5 years in the TAU group. Other baseline 
demographic characteristics are shown in Table 1. 
At three months and one year no differences were found 
between the two groups in the primary outcome measure, 
frequency of cannabis misuse. There were no differences 
between the two groups in any of the secondary outcome 
What is a randomised controlled trial (RCT)?
An RCT is an epidemiological study in which 
participants are randomly allocated to a study group 
or a control group to receive or not to receive an 
intervention (such as an experimental treatment, 
drug or procedure). The results are assessed by 
measuring and comparing the outcomes (rates 
of disease, death, or recovery) in the study and 
control groups. RCTs are considered the most 
scientifically rigorous method for testing new or 
experimental interventions, but they are not without 
their limitations. They may lack generalisability if, 
for instance, the participants recruited are not fully 
representative of the population. 
What is intention-to-treat analysis?
This is the principal method used to analyse subjects 
in an RCT. All participants, as randomised into either 
study or control group, are analysed by group, 
whether or not they actually received or completed 
the intervention. If this method is not used, there is 
the risk of introducing serious bias into the results of 
the study. Intention-to-treat analysis is essential if the 
objective of the study is to influence clinical or public 
health practice, but it can underestimate the efficacy 
of an intervention. 
Source: Porta M (ed.) (2008) A Dictionary of 
Epidemiology. 5th Edition. Oxford: Oxford University 
Press. pp. 130 and 206.
Table 1 Baseline demographic characteristics of 
participants
GPI TAU
Mean Mean
Age (years) 27.6 28.2
Duration of untreated 
psychosis (months) 14.4 12.2
n (%) n (%)
Gender
Male 46 (78) 23 (79)
Female 13 (22) 6 (21)
Education
Primary 3 (5) 0 (0)
Secondary 26 (44) 11 (38)
Third level 24 (41) 15 (52)
Masters/professional 6 (10) 3 (10)
Employed 17 (29) 10 (35)
Diagnosis
Schizophrenia 25 (42) 13 (44)
Schizophreniform disorder 6 (10) 3 (10)
Bipolar disorder 10 (19) 4 (16)
Schizoaffective disorder 1 (2) 0 (0)
Delusional disorder 2 (3) 3 (10)
Brief psychotic disorder 3 (5) 3 (10)
Major depressive disorder 5 (9) 1 (3)
Substance-induced disorder 3 (5) 2 (7)
Psychosis not otherwise specified 4 (7) 0 (0)
Source: Adapted from Madigan et al. (2013)
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Trial of intervention for psychosis with cannabis dependence (continued)
measures, with the exception of subjective quality of life 
scores, which were significantly higher in the GPI group 
at both three months and one year compared to the TAU 
group. This is noteworthy as research shows that a reduction 
in negative outlook is an important outcome of treatment 
for people with schizophrenia. 
The authors state that this is the first randomised controlled 
trial to look at group-based psychological interventions to 
reduce cannabis use among those in the early stages of a 
psychotic illness. The study found that the intervention had 
no effect on reducing cannabis use. The authors suggest 
that the intervention may have been given for too short a 
period (18 weeks) to have sufficient impact on the outcome 
measures. They also point out that they recruited only 88 
participants from 230 patients referred and that they did not 
compare relapse rates between the two groups because of 
variations in admission procedures in the participating 
centres. The authors recommend that more trials involving 
psychological interventions be carried out with this client 
group. 
(Suzi Lyons)
1. Barrowclough C, Haddock G, Wykes T, Beardmore R, Conrod 
P, Craig T et al. (2010) Integrated motivational interviewing 
and cognitive behavioral therapy for people with psychosis 
and comorbid substance misuse: randomized controlled 
trial. BMJ, 341: c6325. www.bmj.com/content/341/bmj.
c6325
2. Madigan K, Brennan D, Lawlor E, Turner N, Kinsella A, 
O’Connor JJ, Russel V, Waddington J, O’Callaghan E* (2013) 
A multi-center, randomized controlled trial of a group 
psychological intervention for psychosis with comorbid 
cannabis dependence over the early course of illness. 
Schizophrenia Research, 143: 138–142. 
* Professor Eadbhard O’Callaghan died in in May 2011 and 
the article is dedicated to his memory.
Substance misuse in the eastern 
counties of HSE South 
The Health Service Executive (HSE) South published the 
report Data co-ordination overview of drug misuse 2011 
in November 2012.1 This overview reports on treated 
substance misuse in the south-eastern counties of Carlow, 
Kilkenny, South Tipperary, Waterford and Wexford.  
The report comprises sections relating to treatment  
services and substance-related offences in the region. 
The section on treatment services analyses data collected 
from statutory and voluntary drug and alcohol treatment 
agencies, acute general hospitals and psychiatric hospitals 
in the region. Data from the drug and alcohol treatment 
services are returned to the National Drug Treatment 
Reporting System in the Health Research Board. 
The total number of individuals seeking treatment in 2011 
was 3,736, an increase of 218 on the 2010 figure. Some 
217 concerned persons (family members or close friends of 
substance users) contacted treatment services in the south 
east in 2011.
Excluding clients who were assessed only and those who 
were treated for addictions other than substance misuse, the 
combined total of continuous care clients and new referrals 
treated for substance misuse in 2011 was 3,022. Of these: 
 ■ 69% were male and 31% were female.
 ■ 7% were under the age of 18, and 22.5% were aged 
between 18 and 24. 
 ■ 57% were aged under 35.
 ■ Alcohol (61%) was the most common main problem 
substance for which treatment was sought, followed 
by cannabis (16%), heroin (15%), and cocaine (3%). 
Heroin, which had been second in this ranking between 
2008 and 2010, was overtaken by cannabis in 2011.
 ■ Between 2010 and 2011 the number of clients treated 
for alcohol as their main problem substance increased 
by 15%, the number treated for cannabis use increased 
by 9% and the number treated for benzodiazepine use 
increased by 21%. The figures for treated cocaine use 
continued to fall, with a decrease of 32% between 2010 
and 2011. 
A total of 2,540 clients exited the services in 2011. Less 
than half (41%) of these clients completed treatment; 30% 
refused further sessions or did not return for subsequent 
appointments; 14% did not wish to attend further sessions 
as they considered themselves to be stable; 9% were 
transferred to another site for further treatment; 2% exited 
because of non-compliance, 3% exited for other reasons, 
and 0.6% had died.
(Ita Condron)
1. Kidd M (2012) Data co-ordination overview of drug misuse 
2011. Waterford: HSE South. www.drugsandalcohol.ie/19088
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Approaches to drug decriminalisation in 
disparate countries
As part of its campaign, ‘Drugs – it’s time for better laws’, 
the UK-based advocacy group Release has published a 
report, A quiet revolution: drug decriminalisation policies in 
practice across the globe.1 The report identifies a trend over 
the past decade towards the decriminalisation of drug 
possession and use, suggesting a ‘growing recognition of the 
failures of the criminalisation approach and a strengthening 
political wind blowing in the direction of an historic 
paradigm shift’ (p.9).
Although the decriminalisation of drug possession and 
use in Portugal in 2001 has attracted a good deal of 
attention throughout Europe,2 the report shows that the 
trend towards decriminalisation has not been centred in 
one continent or in richer or poorer nations: ‘Countries 
as disparate as Armenia, Belgium, Chile, the Czech 
Republic, Estonia, Mexico’ have all adopted some form of 
decriminalisation (p.9). The report describes and assesses 
decriminalisation approaches in 21 countries. It presents 
case studies from jurisdictions that have adopted ‘good 
models of decriminalisation and those that have adopted 
what could be described as hollow examples’ where ‘the 
possession thresholds are so low that the system is effectively 
unenforceable and most people are criminalised’ (p.13).
The decriminalisation policies and models adopted in 
different countries are extremely varied, which renders an 
assessment of their impact quite challenging. The impact of 
decriminalisation on such factors as ‘prevalence of drug use, 
problematic drug use, drug-related disease and death, and 
criminal justice costs’ is complicated by the wide range of 
policy variables adopted in different countries (p.10). These 
variables include the following:
 ■ Threshold quantities: Many policies use maximum-
quantity thresholds to distinguish between trafficking 
and personal possession offences. For example, ‘Mexico 
allows possession of up to 0.5 grams of cocaine without 
prosecution, while Spain allows up to 7.5 grams – a 
difference of 1400%’.
 ■ Types of administrative penalties: Different sanctions 
for possession offences may include ‘fines, community-
service orders, warnings, education classes, suspension of 
a driver’s licence…travel bans…administrative arrest, or 
no penalty at all’.
 ■ Roles of the judiciary and police: Some jurisdictions allow 
the police to issue an ‘on the spot’ penalty while others 
require the offender to appear before a judge. 
 ■ The role of medical professionals and harm reduction 
programmes: Some countries, such as Portugal, have 
integrated public health and law enforcement systems 
so that offenders appear before a panel that includes 
medical professionals for an assessment of their 
treatment needs.
 ■ Records and statistics-measurement capacity: 
The availability and quality of data in the system 
can determine the ‘assessment of the impact of a 
decriminalisation policy’. 
 ■ Implementation challenges: The introduction of a 
decriminalisation policy in law can be undermined and 
effectively neutralised where law enforcement refuses to 
apply it in practice. The report gives the example of 
New York where 
possession of one 
ounce of marijuana 
is not a crime 
unless the drug is 
‘burning or in open 
view’. However, it is 
reported that police 
officers ‘often trick 
young people…
into revealing the 
marijuana; thus the 
offence is committed 
as the drug is in 
“open view” ’ (p.11). 
The authors state 
that this practice ‘has 
led to a significant 
increase in arrests, 
with 50,300 people arrested for simple marijuana possession 
in 2010 alone compared to a total of 33,700 for the period 
1981 to 1995’ (p.11) 
Despite these many policy variables however, the report 
does offer a number of broad observations. Acknowledging 
that ‘decriminalisation is not a panacea’ for problematic 
drug use, it states that ‘a country’s drug enforcement 
policies appear to have but a minor effect on the impact of 
drugs in a society. … Decriminalisation does appear to direct 
more users into treatment, reduce criminal costs, and shield 
many drug users from the devastating impact of a criminal 
conviction’ (p.12).
Based on the case studies provided in this report, the authors 
conclude that ‘governments and academics must invest 
more in researching which policy models are the most 
effective in reducing drug harms and achieving just and 
healthy policy outcomes’. In proposing such an evidence-
based approach, they state that ‘more and better data will 
bolster the existing research and provide a sound foundation 
on which to build and design drug policies of the future’ 
(p.40). 
Although drug law reform has never been high on the 
political agenda in Ireland, a recent policy document 
launched by the CityWide Drugs Crisis Campaign calls for a 
debate on drug decriminalisation.3 Topics for such a debate 
include the view that ‘much of the harm related to drug use 
and drug dealing occurs because of their illicit nature’ and 
that ‘the global war on drugs has failed and it is time for us 
to challenge rather than reinforce common misconceptions 
about drug markets, drug use and drug dependence’ (p.5)
(Johnny Connolly)
1. Rosmarin A and Eastwood N (2012) A quiet revolution: drug 
decriminalisation policies in practice across the globe. London: 
Release. www.drugsandalcohol.ie/18327
2. Connolly J (2009) Reports examine effects of 
decriminalisation of drugs in Portugal. Drugnet Ireland, 30: 
22–23. www.drugsandalcohol.ie/12204
3. Higgins M (2012) The drugs crisis in Ireland: a new agenda 
for action. CityWide policy statement February 2012. Dublin: 
CityWide. www.drugsandalcohol.ie/17145
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Investigating the links between substance 
misuse and crime 
A report by the Probation Service presents the findings of the 
first large-scale, nationwide survey conducted by the service on 
drug and alcohol misuse among the adult offender population 
on probation supervision.1 Although earlier research in Ireland 
has highlighted a link between substance misuse and offending 
behaviour,2 the identification of the precise causal connection 
between drugs and crime remains a complex and much-debated 
area of criminological research.3 
A better understanding 
of the nature of the 
connection between drug 
use and offending has 
implications for drug and 
crime prevention and for 
treatment and criminal 
justice interventions. A 
major impediment to 
research in this area in 
Ireland, however, is the 
absence of data from within 
the criminal justice system. 
For example, it is clear 
from prison drug seizures, 
prison drug testing and 
methadone maintenance 
uptake in prison, that a 
significant proportion 
of Irish prisoners are 
problematic drug users.4 
We also know from data provided in the annual reports of the 
Irish Prison Service the number of people imprisoned for drug 
offences under the Misuse of Drugs Acts, such as drug possession 
or supply. However, most problematic drug users are imprisoned 
not for breaches of the drug laws but for drug-related offences, 
that is, offences such as theft committed as a consequence of 
their addiction, to fund their drug habit. It is in highlighting this 
particular aspect of the drugs–crime nexus that this report is 
particularly important.
The survey involved a representative sample of 2,963 adult 
offenders on probation officers’ caseloads on 1 April 2011. 
Questionnaires, developed specifically for the purpose of the study 
were completed by the supervising probation officers, based 
on their case records and knowledge of the offenders on their 
casebooks. 
The main objectives of the study were as follows: 
 ■ Ascertain the number of adult offenders on probation 
supervision who misuse drugs and/or alcohol. 
 ■ Examine the nature and frequency of drug and alcohol misuse.
 ■ Establish if there is a correlation between drug and/or alcohol 
misuse and offending behaviour.
 ■ Identify the level and nature of engagement with drug and 
alcohol treatment services. 
Included among the key findings in relation to the first two aims 
(p.4) are the following:
 ■ 89% of the adult offender population on probation supervision 
had misused drugs or alcohol either ‘currently’ (at the time of 
the survey) or in the ‘past’. 
 ■ Of those who misused either alcohol/drugs, 27% misused drugs 
only, 20% misused alcohol only and 42% misused both drugs 
and alcohol. 
 ■ While females comprised only 12% of the adult offender 
population, both male and female adult offenders exhibited 
similar drug and alcohol misuse levels. 
 ■ The Dublin probation regions exhibited the highest levels of 
overall misuse among their offender populations, at 91%. 
 ■ Almost 21% of offenders were currently misusing two or 
more substances and over 9% were misusing at least three 
substances. This includes misuse of alcohol. 
Chapter five of the study considers the relationship between drug/
alcohol misuse and crime among the adult offender population on 
probation. The study found that, based on the probation officers’ 
professional judgement, ‘there were a substantial number of 
cases where drug misuse (74%) and alcohol misuse (71.3%) were 
linked to the offence committed’, although the author adds the 
important caveat that the complexity of the issue meant that a 
‘strong association’ between the drug use and the offence should 
not be interpreted as meaning that one necessarily caused the 
other (p.38). In this respect, and consistent with other research in 
this area, the study found that many ‘other factors associated with 
offending behaviour’, such as ‘the offender’s anger…mental health 
and mild learning difficulties…disrupted family background, lack of 
parental control, low education, child abuse and domestic violence 
were also stated as risk factors in offending behaviour’ (p.38). 
With regard to gender issues, the study found that drug misuse 
among female offenders was marginally more likely to be linked 
to the offence than that among male offenders; the opposite was 
the case in relation to the link between alcohol and the offence 
committed. The study also found that the link between drug 
misuse and offending was more pronounced among the younger 
age groups. In terms of the offence type, of those whose drug 
misuse and offence were linked, 31% of offences were drug law 
offences (such as drug possession), while 36.8% were linked to 
acquisitive crimes (theft, burglary, robbery, property offences) 
(p.33). The study also highlights the link between alcohol and 
crime, particularly violent and public-order-related crime: the 
alcohol misuse of 71% of alcohol-misusing offenders was linked to 
the current offence committed, and the majority of alcohol-related 
offences were crimes against the person and public order offences, 
at almost 40% (p.37).
The final aim of the study was to consider treatment uptake among 
the offender population. It found that ‘of those who misused drugs, 
48.4% appeared to be not currently engaging with any drug 
treatment service’ (p.42). It is unclear why this is the case as the 
views of offenders were not incorporated into the study, one of the 
acknowledged limitations of the research (p.8). Nevertheless, this 
study is an important contribution towards the development of 
evidence-based criminal justice interventions in response to crime 
related to drug and alcohol misuse. 
(Johnny Connolly)
1. The Probation Service (2012) Drug and alcohol misuse among adult 
offenders on probation supervision in Ireland: findings from the drugs 
and alcohol survey 2011. Navan: The Probation Service.  
www.drugsandalcohol.ie/18746
2. Two important early studies are: O’Mahony P (1997) Mountjoy 
prisoners: a sociological and criminological profile. Dublin: Stationery 
Office; Keogh E (1997) Illicit drug use and related criminal activity in 
the Dublin Metropolitan Area. Research Report No. 10/97. Dublin: 
An Garda Síochána. 
3. For a discussion see Connolly J (2006) Drugs and crime in Ireland. 
HRB Overview Series 3. Dublin: Health Research Board.
4. For a broader discussion on this issue see Health Research Board 
(2011) 2011 National Report (2010 data) to the EMCDDA by the 
Reitox National Focal Point. Ireland: new developments, trends and in-
depth information on selected issues. Dublin: Health Research Board. 
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This report, Driving under the influence of drugs, alcohol and medicines in Europe 
– findings from the Druid project, presents the key findings from one of the most 
comprehensive research projects ever carried out in the EU on drugs (including 
alcohol) and driving.1 The DRUID research project was established in September 2006 
with the aim of estimating the size of the drug-driving problem in a comparable way 
across Europe and to examine the range of appropriate countermeasures. The project 
ran for five years and involved 38 consortium partners from 17 EU member states 
and Norway. The project deliverables include 50 research reports and these inform its 
recommendations, which look at measures to combat alcohol-impaired driving, illicit 
drug-impaired driving and medicine impaired driving.2
(Johnny Connolly)
1. EMCDDA (2012) Driving under the influence of drugs, alcohol and medicines in Europe – 
findings from the DRUID project. Luxembourg: Publications Office of the European Union. 
www.drugsandalcohol.ie/19002
2. These reports are listed in Annex 3 of the publication and can be downloaded from the 
DRUID project website at www.druid-project.eu
Driving under the influence in Europe
Vocational training, employment  
and addiction recovery 
The Report of the working group on drugs rehabilitation1 
recommends that measures to improve the employability 
of current, former and recovering drug users should form a 
key part of rehabilitation care plans, with the overall aim ‘to 
maximise the quality of life, re-engagement in independent 
living and employability of the recovering problem drug 
user, in line with their aspirations’ (p.21). Action 32 of the 
National Drugs Strategy2 calls for implementation of the 
working group’s recommendations. The current Programme 
for Government3 includes a commitment ‘to assist drug 
users in rehabilitation through participation in suitable local 
community employment schemes’ (p.50). 
However, the most up-to-date report on the employment 
status of people presenting for treatment for drug misuse 
shows a steady trend downwards.4 According to the 
authors, there was a ‘drop in the proportion of all cases in 
employment, from 22% in 2005 to 9% in 2010 (Table 1). 
Table 1 Number and percentage of treated cases in employment, 2005–2010
2005 2006 2007 2008 2009 2010
n % n % n % n % n % n %
All cases 1025 (21.8) 1071 (21.0) 1059 (18.9) 921 (15.0) 689 (10.9) 670 (9.1)
New cases 542 (29.7) 590 (28.0) 592 (25.6) 524 (20.8) 386 (13.9) 357 (11.7)
Source: Bellerose et al. 2011
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This is most likely a reflection of the current economic climate, 
and highlights the continued importance of social and 
occupational reintegration interventions as part of the drug 
treatment process’ (p.2). 
There was an even greater drop in the proportion of new 
cases (those presenting for treatment for the first time) 
who were in employment, from 29.7% in 2005 to 11.7% in 
2010. 
A comprehensive review of the literature on unemployment 
and substance use spanning the period 1990–20105 found 
that (i) problematic substance use increases the likelihood 
of unemployment and decreases the chances of finding and 
retaining a job, (ii) unemployment is a significant risk-factor 
for substance use and the subsequent development of 
substance use disorders, and (iii) unemployment increases 
the risk of relapse after treatment. 
The logic of this aspiration to improve employment 
prospects for individuals affected by the use of drugs is 
supported by research from the US,6 which found that clients 
in employment stayed in treatment longer and achieved 
better outcomes than their unemployed counterparts. 
There is no ‘gold standard’ in vocational interventions or 
programmes for any client population or treatment modality 
in the addiction field, although some initiatives, primarily in 
the US, have shown promise. 
Measures taken to improve the employability of recovering 
drug users in Ireland through Special Community 
Employment schemes have been reviewed in recent 
years.7,8,9 All three reviews concluded that the scheme was 
less focused on improving employability and more inclined 
to operate in a crisis management mode by providing 
generic support to recovering drug users. 
A 2012 review of the literature on vocational training 
for drug users in treatment10 refers to a 2004 review and 
synthesis of three decades of research in this area11 and 
concludes that: ‘Most interventions reviewed were shown 
to have no significant effects, limited effects or results that 
were confounded by poor study design’ (p.95). The 2012 
review did not uncover any research in the intervening years 
that disputed this conclusion. Furthermore, the authors 
highlight the lack of rigorous evaluation of vocational 
training interventions for recovering drug users in Europe 
and caution against drawing inferences of transferability 
from studies undertaken outside the European context. 
They describe a number of primary studies from within 
the European context and beyond, but claim that because 
of differences in approach it is not possible to draw any 
meaningful conclusions about their effectiveness. 
Despite the lack of consensus in the literature on ‘what 
works’ to improve employability among drug users in 
treatment, there remains a commitment among policy 
makers and practitioners to support drug users in accessing 
and maintaining employment. This commitment is 
important, as the benefits that accrue from being in 
employment are well documented. For example, one study 
identified the benefits that can contribute to an individual’s 
ability to create and sustain a drug-free life.12 According to 
the authors (p.38), being in paid employment:
 ■ enables the recovering drug user to fill his or her time 
constructively 
 ■ promotes economic independence 
 ■ helps reintegration to wider society by moving the 
individual away from the drug-using network and 
towards drug-free social relationships 
 ■ enhances self-esteem and helps build new sense of self, 
which protects against relapse 
 ■ conveys status, which acts as an important symbol to 
the individual of their ability to return successfully to a 
conventional life. 
On the other hand, the challenges facing recovering 
drug users in their attempts to gain employment are well 
documented in two studies that highlight the continuing 
interplay of personal and structural barriers that often 
prevent recovering drug users from accessing and securing 
paid employment.13,14 
(Martin Keane) 
1. Working Group on drugs rehabilitation (2007) National 
Drugs Strategy 2001–2008: rehabilitation. Dublin: 
Department of Community, Rural and Gaeltacht Affairs.  
www.drugsandalcohol.ie/6267
2. Department of Community Rural and Gaeltacht Affairs 
(2009) National Drugs Strategy (interim) 2009–2016. Dublin: 
Department of Community, Rural and Gaeltacht Affairs.  
www.drugsandalcohol.ie/12388
3. Fine Gael and the Labour Party (2011) Towards recovery: 
programme for a national government 2011–2016. Dublin: 
Fine Gael, and the Labour Party.  
www.drugsandalcohol.ie/14795
4. Bellerose D, Carew AM and Lyons S (2011) Trends in treated 
problem drug use in Ireland 2005–2010. HRB Trends Series 
12. Dublin: Health Research Board.  
www.drugsandalcohol.ie./16381
5. Henkel D (2011) Unemployment and substance use: a 
review of the literature (1990–2010). Current Drug Abuse 
Reviews, 4(1): 4–27. 
6. Platt JJ (1995) Vocational rehabilitation of drug abusers. 
Psychological Bulletin, 117(3): 416–433.
7. Bruce A (2004) Drugs task force project activity for FÁS 
Community Employment and Job Initiative participants. Dublin: 
FÁS. www.drugsandalcohol.ie/6020
8. Lawless K (2006) Listening and learning: evaluation of special 
community employment programmes in Dublin North East. 
Dublin: North Dublin City and County Regional Drugs Task 
Force. www.drugsandalcohol.ie/6122
9. Van Hout MC and Bingham T (2011) Holding pattern: 
an exploratory study of the lived experiences of those on 
methadone maintenance in Dublin North East. Dublin: Dublin 
North East Drugs Task Force.  
www.drugsandalcohol.ie/16231
10. Sumnall H and Brotherhood A (2012) Social reintegration 
and employment: evidence and interventions for drug users in 
treatment. Luxembourg: Publications Office of the European 
Union. www.drugsandalcohol.ie/18596 
11. Magura S, Staines G, Blankertz L and Madison E (2004) The 
effectiveness of vocational services for substance users in 
treatment. Substance Use and Misuse, 39(13&14): 2165–
2213. 
12. McIntosh J, Bloor M and Robertson M (2008) Drug 
treatment and the achievement of paid employment. 
Addiction Research and Theory, 16(1): 37–45.
13. Bauld L, Hay G, McKell J and Carroll C (2010) Problem drug 
users’ experiences of employment and the benefit system. 
Research Report No. 640. Norwich: HM Stationery Office.
14. Simonson P (2010) Pathways to employment in London: a 
guide for alcohol and drug services. London: Drugscope.
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Soilse graduation 
Soilse, the HSE’s Addiction Rehabilitation Service based in 
Dublin, held a graduation event on 28 February 2013 at 
their premises in Green Street, Dublin 7. Alex White TD, 
Minister of State with responsibility for the national drugs 
strategy presented FETAC certificates to 22 former Soilse 
participants. Of these, nine received a major award at Level 
3, and six received Level 5 awards. The FETAC certificates 
recognise academic work by the participants during their 
time in Soilse.
Minister of State Alex White TD at the Soilse Project graduation event with, from left: Mel MacGiobúin, Co-ordinator of the North 
Inner City Drugs Task Force (NICDTF); Martin Keane, Health Research Board; Gerry McAleenan, Manager of Soilse; Joe Barry, 
Chairman of the NICDTF; and Tom O’Brien, HSE Addiction Services Manager.
‘Let’s talk about drugs’
The ‘Let’s talk about drugs’ National Media Awards 
competition encourages public discussion of drug-related 
issues by inviting secondary school students and aspiring 
journalists to create a feature about drugs. The age 
categories are 12–14, 15–17, 18–20, and 21+. 
Co-ordinated by the Greater Blanchardstown Response 
to Drugs, the competition is free to enter and is being 
supported by Drugs.ie, the HSE, the Department of Health, 
Crimestoppers and the Irish Examiner.
John O’ Mahony, News Editor of the Irish Examiner, is joining 
the judging panel this year. Henry McKean from Newstalk 
106–108fm and Caroline Twohig from the television 
channel, 3e, are also on the panel.
Themes for 2013
 ■ Theme 1: Alcohol and sport – who is the real winner?
 ■ Theme 2: Weed and health – are we making a hash of it?
Media categories
 ■ Newspaper article
 ■ Video/animation feature
 ■ Audio recording
 ■ Cartoon
 ■ Special Poster Category 
Poster to include the message: 
‘If you have information on Drug Dealing you can call 
Crimestoppers on Freephone 1800 25 00 25.’
How to enter
Pick one of the themes above and create a piece of original 
content, based on your chosen theme, in a format suitable 
for one of the media  categories listed. Read the Tips on 
Entering and Terms and Conditions, and then fill in the entry 
form. There are no entry fees. 
Deadline and prizes
Get your entry in by Friday 31 May 2013 and be in with 
a chance to win €1,000 and have your work published or 
broadcast! All category winners will receive an Android tablet 
and trophy.
Get more information at  
www.drugs.ie/resources/awards/about_the_awards
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In brief
On 16 November 2012 Dealing with the stigma of drugs: 
a guide for journalists was issued by the UK Drug Policy 
Commission and the Society of Editors. Rather than telling 
editors and journalists what to think or say or write, this guide 
sets out to explain the problem and to help journalists report 
accurately and objectively so that stigma born of ignorance can 
be replaced with proper understanding and support for drug 
users. www.ukdpc.org.uk or www.societyofeditors.org 
On 27 November 2012 the UN General Assembly 
unanimously agreed to hold a General Assembly Special 
Session (UNGASS) to review current policies and strategies 
to confront the global drug problem. Ninety-five UN member 
countries sponsored the draft resolution, presented by Mexico, 
on international co-operation on the global problem of drugs, 
including various countries in Latin America and the Caribbean 
and in the European Union, as well as Japan, China, Australia, 
and the United States. The UNGASS will take place at the 
beginning of 2016 after an intense preparatory process.  
The last UNGASS on drugs took place 14 years ago, in 1998. 
UN General Assembly 4 December 2012, A/67/459
On 29 November 2012 Growing up in Ireland. Key findings: 
13-year-olds. No 4. The lives of 13-year-olds: their relationships, 
feelings and behaviours was launched at the 4th annual 
Growing Up in Ireland Research Conference in Dublin. It reports 
on data from the second wave of interviews with Growing Up 
in Ireland’s Child Cohort. The children and their families were 
first interviewed when the children were nine years old, and 
then again at age 13 years, between August 2011 and February 
2012. In general, 13-year-olds had a positive self-image. Boys 
had a more positive self-image than girls. An exception to 
this was the higher self-image that girls had in terms of their 
behaviour, indicating less problematic behaviours among 
girls than boys. A very large majority (91%) of 13-year-olds 
had never smoked a cigarette, 7% had smoked at some point 
but not in the last year and 2% said they currently smoked. 
Similarly, a large majority (85%) had never taken alcohol.  
A small percentage (0.6%) of 13-year-olds recorded that they 
drank alcohol once a month or more. www.growingup.ie 
On 30 November 2012 the International Drug Policy 
Consortium (IDPC) published a briefing to highlight the 
effects of drug policy on women as producers, suppliers and 
consumers of drugs, in order to inform and guide policy makers 
on practices that should be avoided, as well as to highlight 
those policies which effectively incorporate and address 
women’s needs. www.idpc.net 
As of 1 December 2012 cigarettes in Australia must be sold 
in plain packaging. Talks on plain packaging began years ago 
with legislation introduced by the Australian Government in 
2011, but almost immediately tobacco companies mounted 
an expensive legal challenge. The legislation was upheld in 
August 2012. News item from The Lancet (1–7 December 
2012), 380(9857): 1896. http://dx.doi.org/10.1016/S0140-
6736(12)62096-0 
On 21 December 2012 the Mid-term review of the National 
Strategy on Domestic, Sexual and Gender-based Violence 
2010–2014 was published. Focusing on implementation of 
the strategy, rather than evaluation, the report found that 
co-ordination, involving co-operation and collaboration, was a 
highly contentious issue: ‘The main divide is in the relationship 
between the statutory agencies and the NGOs …. If allowed to 
continue, this has the potential to impact adversely on strategy 
implementation. There are also challenges with regard to 
collaboration between the national level and regional level …. 
[and] evidence of some issues or tensions within sectors.’  
www.cosc.ie 
In December 2012 the Irish Youth Justice Service published 
its Report on the implementation of the National Youth Justice 
Strategy 2008–2010. It concludes: ‘We can now say that a) 
we know more about the nature of the youth crime problem 
and this has allowed us to be more data driven and evidence 
informed, b) this has corresponded with a falling detected 
youth crime rate, c) these positive changes have occurred 
at the same time as Ireland’s relatively low level of youth 
detention has also experienced further downward trends and 
d) this correlates with a more effective use of money and offers 
the prospect of better outcomes for children and communities.’ 
www.iyjs.ie 
In January 2013 the British Medical Association’s Board 
of Science published a report Drugs of dependence: the 
role of medical professionals. It says the focus on health is 
currently ‘inadequate’, warning that some users may be 
discouraged from seeking help for fear of being treated as 
criminals. Produced with the help of an expert reference 
group of specialists, the report examines the legal framework 
underpinning the current strategies and assesses the role that 
doctors and other medical professionals have in tackling drug 
misuse. It says that people who are addicted to illegal drugs 
have a medical condition that should be treated like any other 
illness, and it adds that doctors should help to refocus the 
debate to ensure that it is based on public health principles  
and results in ‘better health outcomes for all illicit drug users’. 
www.bmj.com/content/346/7891 or  
www.drugsandalcohol.ie/19112.
On 10 February 2013 Bolivia re-acceded to the 1961 
Single Convention on Narcotic Drugs, as amended, with a 
reservation on the chewing of coca leaf, a traditional practice 
among its people. Bolivia had withdrawn from the Convention 
on 1 January 2012. Its re-accession could have been blocked 
if a third of the 183 states party to the Convention, that is 61 
states, objected to the proposed reservation by the deadline 
of 10 January 2013. Only 15 countries (United States, Mexico, 
Japan, Russia, Canada, the UK, Germany, France, Italy, the 
Netherlands, Sweden, Finland, Portugal, Israel and Ireland) 
objected, and thus the reservation was permitted.  
www.unodc.org 
On 11 February 2013 the RAND Drug Policy Research 
Center hosted a conference Developing public health 
regulations for marijuana: lessons from alcohol and tobacco. 
With the states of Colorado and Washington both passing 
initiatives to legalise the commercial production, distribution, 
and possession of marijuana for non-medical purposes, US 
policymakers now need to better understand the possible 
consequences of these decisions. Rather than asking whether 
these state initiatives were good or bad, the session focused 
on the multitude of regulatory issues facing agencies trying to 
design a comprehensive policy. There was a special focus on 
how different alcohol and tobacco regulations (e.g. licensing, 
advertising restrictions, user/sales restrictions) influence youth 
access and minimise public health harms.  
www.rand.org/multi/dprc.html 
(Compiled by Brigid Pike)
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From Drugnet Europe
Drug policy profile — Ireland
Cited from Drugnet Europe, No. 81, January–March 2013
The national drug policy of Ireland comes under the 
spotlight in the latest volume in the EMCDDA series of 
Drug policy profiles published in February. Examining the 
evolution of Irish drug policy through four periods of historic 
development, the report explores: the country’s national 
strategies; the legal context within which they operate; the 
public funds spent, or committed, to implement them; and 
the political bodies and mechanisms set up to coordinate the 
response to the problem. The profile sets this information 
in context by outlining the size, wealth and economic 
situation of the country as a whole, as well as the historical 
development of the current policy. Also described is the 
manner in which events in Ireland bear similarities with, 
and differences from, developments in other European 
countries. This EMCDDA series aims to describe some of the 
main characteristics of national drug policies in Europe and 
elsewhere in the world. The profiles do not attempt to assess 
national policies, but instead outline their development and 
main features. 
www.emcdda.europa.eu/publications/drug-policy-profiles/
ireland
Measuring daily cannabis use
Cited from article by Danica Thanki in Drugnet Europe, No. 
81, January–March 2013
A recent EMCDDA Thematic paper entitled Prevalence of 
daily cannabis use in the European Union and Norway presents 
a new overview of this issue in Europe. Daily cannabis 
consumption is defined in the study as use on 20 days 
or more in the month preceding interview. Self-reported 
data regarding the frequency of cannabis use from large, 
probabilistic, nationally representative samples of general 
population surveys were collected from 20 countries. … 
The analysis offered by the report enhances our 
understanding of the marked increases in the demand for 
treatment associated with cannabis problems over the last 
15 years. The study found that, on average, 25% of last-
month cannabis users consume the substance daily. This 
pattern of use is more prevalent among young adults (15–34 
years), who represent around 70% of daily users, and 
among males (almost 3.5 male cases to one female case). 
The EMCDDA estimates that there are around 3 million 
daily cannabis users in the EU and Norway. Relatively large 
country variations in prevalence exist.
For more, see www.emcdda.europa.eu/publications/
thematic-papers/daily-cannabis-use
Multidimensional family-therapy and cannabis use
Article by Marica Ferri in Drugnet Europe, No. 81, January–
March 2012
The EMCDDA has recently conducted a meta-analysis 
of a multi-site European study and US studies on 
multidimensional family-therapy (MDFT). This integrative, 
family-based treatment is specifically targeted at adolescent 
drug use and related behavioural problems. Encouraging 
results have been noted in particular with MDFT and young 
cannabis users. Users enrolled in this type of treatment were 
seen to attend all scheduled sessions and, as a result, to 
reduce their cannabis consumption and to experience fewer 
symptoms of dependence. These results are of particular 
importance considering the rising demand for the treatment 
of cannabis use in Europe (see above).
MDFT will be one of the issues examined later this year 
in a new EMCDDA Insights publication on the Treatment 
of cannabis-related disorders and will be the subject of an 
upcoming EMCDDA Thematic paper.
See the EMCDDA Best Practice portal www.emcdda.europa.
eu/best-practice/treatment/cannabis-users
Drugnet Europe is the quarterly newsletter of the 
European Monitoring Centre  
for Drugs and Drug Addiction (EMCDDA).  
Drugs in focus is a series of policy briefings published by 
the EMCDDA. Both publications are available at  
www.emcdda.europa.eu.
If you would like a hard copy of the current or 
future issues of either publication, please contact: 
Health Research Board, Knockmaun House,  
42–47 Lower Mount Street, Dublin 2.  
Tel: 01 2345 148; Email: drugnet@hrb.ie
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Recent publications
Journal articles
The following abstracts are cited from recently published journal articles relating to the drugs situation in Ireland.
An alcohol and other drugs library: building capacity and 
adding value 
Dunne M  
Addiction, 2013, 108(2): 431–432  
www.drugsandalcohol.ie/19172
Letter to the Editor: Staff of the National Documentation 
Centre on Drug Use (NDC) outline how a special alcohol 
and other drugs (AOD) library may provide considerable 
added value to those researching and working in this area.
The Irish National Drugs Strategy is unusual as it includes 
research as one of its five pillars. This recognises the need to 
have a thorough knowledge of the drugs situation and to 
respond in an evidence-based way. The NDC was created 
to facilitate this approach. Through our online repository, 
we provide access to all relevant Irish news, journal articles, 
reports, books, theses, conference proceedings and 
parliamentary debates. The collection has grown from 1,200 
bibliographic records in 2002 to more than 10, 000 records 
in 2012.
Behavioural change in relation to alcohol exposure in 
early pregnancy and impact on perinatal outcomes – a 
prospective cohort study 
Murphy D, Mullaly A, Cleary B, Fahey T and Barry J  
BMC Pregnancy and Childbirth, 2013, 13(8)  
www.drugsandalcohol.ie/19224
This study involved 6725 women who booked for antenatal 
care and delivered in a large urban teaching hospital in 
2010–2011. A detailed history of alcohol consumption pre-
pregnancy and during early pregnancy was recorded at the 
first antenatal visit, with follow-up of the mother and infant 
until discharge following birth. Adverse perinatal outcomes 
were compared for ‘non-drinkers’, ‘ex drinkers’ and ‘current 
drinkers’. Factors associated with continuing to drink in early 
pregnancy were examined.
Of the 6017 (90%) women who reported alcohol 
consumption prior to pregnancy 3325 (55%) engaged in 
binge drinking and 266 (4.4%) consumed more than 14 
units on average per week. At the time of booking 5649 
(94%) women were ex-drinkers and of the 368 women 
who continued to drink 338 (92%) had a low intake (0–5 
units per week), 30 (8%) an excess intake (6-20+ units per 
week) and 93 (25%) reported at least one episode of binge 
drinking. 
The authors conclude that Public Health campaigns need to 
emphasise the potential health gains of abstaining from both 
alcohol and smoking in pregnancy.
The journey into injecting heroin use 
Barry D, Syed H and Smyth BP  
Heroin Addiction and Related Clinical Problems, 2013, 14(3): 
89–100  
www.drugsandalcohol.ie/19149
Drug injection carries with it many risks and it is therefore 
important to understand its origins. We interviewed 104 
young opioid users with median age of 22 years. The 
median age of first opioid use was 16 years, this being 
heroin chasing in 91% of cases. Friends or sexual partners 
played an important role in both initial introduction to 
opiates and in the switch to injecting. Curiosity was the most 
important factor in first heroin use and the second most 
important factor, after escalating tolerance, in influencing 
the decision to first inject.
Avoiding action: Ireland, alcohol, intoxication and 
workplace safety 
Houghton F  
Irish Journal of Medical Science, 2012, 29 November, Online 
first  
www.drugsandalcohol.ie/19079 
Letter to the Editor: The latest Summary of workplace injury, 
illness and fatality statistics from the Health and Safety 
Authority (HSA) makes for sobering reading. As well as 54 
fatalities, 6,956 non-fatal injuries were reported to the HAS 
in 2011. The report also notes that based on CSO data, 
there were an estimated 666,553 days lost due to injury in 
2010.
However, examination of HSA annual reports and summaries 
of statistics reveals an almost complete absence of the 
mention of alcohol or intoxicants of any kind. ...
Methadone treatment in Irish general practice: voices of 
service users
Latham L  
Irish Journal of Psychological Medicine, 2012, 29(3): 147–156  
www.drugsandalcohol.ie/19006 
This study sets out to make a meaningful contribution to the 
discussion surrounding the treatment of heroin addiction 
in Ireland. The study took place in nine general practices 
in Dublin city. Twenty-five service users were interviewed 
in depth. A phenomenological approach drawing on the 
psychological research methods of Colazzi for data analysis 
informed this study.
Four themes were identified: service user’s experiences of 
attending general practice for methadone treatment; the 
significance of methadone for the service user; service users’ 
understanding of the Methadone Treatment Protocol; and 
the experience of addiction and its effect on families.
This paper reports on the experiences of service users 
receiving methadone treatment in urban general practice 
in Dublin and in so doing highlights the influence of the 
GP in supporting recovery. These accounts provide insight 
into the harm reduction policy of methadone maintenance 
and highlight how, from the service users’ experience, the 
implementation is falling short.
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Recent publications (continued)
Methadone dosing and prescribed medication use in 
a prospective cohort of opioid-dependent pregnant 
women
Cleary BJ, Reynolds K, Eogan M, O’Connell MP, Fahey T, 
Gallagher PJ et al. 
Addiction, 2012, 7 December, Early online  
www.drugsandalcohol.ie/18937 
This study aimed i) to describe methadone dosing before, 
during and after pregnancy, ii) to compare the incidence of 
neonatal abstinence syndrome (NAS) between those with 
dose decreases and those with steady or increasing doses, 
and iii) to describe prescribed medication use among opioid-
dependent pregnant women.
Of 89 women treated with MMT throughout pregnancy, 
36 (40.4%) had their dose decreased from a mean pre-
pregnancy dose of 73.3mg (Standard Deviation 25.5) to a 
third trimester dose of 58.0mg (SD 26.0). The corresponding 
figures for those with increased doses (n=31, 34.8%) were 
70.7mg (SD 25.3) and 89.7mg (SD 21.0), respectively. The 
incidence of medically-treated NAS did not differ between 
dosage groups. Antidepressants were dispensed for 29 
women (25.7%) during pregnancy, with the rate decreasing 
from pre-pregnancy to postpartum. Benzodiazepines were 
prescribed for 43 women (38.0%).
In the Irish health service, opioid-dependent women 
frequently have their methadone dose decreased during 
pregnancy but this does not appear to affect the incidence 
of neonatal abstinence syndrome in their babies.
The symbolic politics of the Dublin drug court: the 
complexities of policy transfer
Butler S  
Drugs: education, prevention and policy, 2013, 20(1): 5–14  
www.drugsandalcohol.ie/18888
This article, based on qualitative interviews with experienced 
professionals and bureaucrats involved in the management 
of drug-using offenders in Ireland, looks at the Dublin 
pilot drug court as an example of policy transfer between 
countries. Those interviewed were generally unconvinced 
that the American drug court model was technically 
more effective than more traditional methods of diverting 
offenders from custodial sentencing into treatment, and 
tended to see political support for the initiative in terms of 
the symbolic value of this liberal, humanistic alternative to 
imprisonment. They also agreed, however, that the Dublin 
drug court was not true to the American model in that it did 
not embody the philosophy of therapeutic jurisprudence 
which is central to American drug court practice.
Situational and psycho-social factors associated 
with relapse following residential detoxification in a 
population of Irish opioid dependent patients
Ducray K, Darker CD and Smyth BP  
Irish Journal of Psychological Medicine, 2012, 29(2): 72–79  
www.drugsandalcohol.ie/18862
This study aimed to identify and describe the context 
and factors involved in the opioid lapse process following 
discharge from an Irish inpatient opioid detoxification 
treatment programme. 
Of 109 people interviewed at follow-up, 102 (94%) reported 
at least one episode of opioid use after leaving the residential 
treatment programme. Eighty eight patients (86% of the 
lapsers) identified more than one major factor contributing 
to their recidivism. The median number of factors identified 
as having a major role in the lapse was four. The most 
frequently reported major contributors to lapse were low 
mood (62%), difficulties with craving (62%), ease of access 
to heroin (48%) and missing the support of the treatment 
centre (43%). 
Conclusions: Early lapse was common following inpatient 
treatment of opioid dependence. Lapse tended to result 
from a number of common, identifiable, high-risk situations, 
feelings and cognitions which may assist clinicians and 
patients develop lapse prevention strategies to anticipate 
and interrupt this process.
Cognitive behavioural coping skills therapy in cocaine 
using methadone maintained patients: a pilot 
randomised controlled trial 
Darker CD, Sweeney B, El Hassan HO, Kelly A and Barry J  
Heroin Addiction and Related Clinical Problems, 2012, 14(3): 
101–110  
www.drugsandalcohol.ie/18861
A pilot randomised controlled trial to test the effectiveness 
of delivering cognitive behavioural coping skills (CBCS) to 
reduce cocaine usage in methadone maintained patients. 
Recruitment was stopped after forty-five patients were 
recruited, with twenty-two randomised to TAU and twenty-
three to CBCS. CBCS group significantly reduced their 
cocaine powder usage compared to the TAU group (DiD = 
-6.65, p<0.03). There was a significant reduction in both 
cocaine powder (DiD = -7.66, p<0.002) and crack cocaine 
(DiD = -4.88, p<0.04) between baseline and follow-up 
across both groups. However, urine toxicology results 
indicate a slightly larger drop in the percentage positive 
urines (relative to baseline) occurred in the TAU group. 
Attendance at counselling sessions was very low, averaging 
25% at CBCS sessions and 13% at TAU sessions. Participants 
who did attend counselling showed a marked decline in the 
proportion of cocaine positive urines (during treatment and 
again at week 52).
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Upcoming events
Compiled by Joan Moore (jmoore@hrb.ie)
April
18 April 2013
Drugs Awareness Training – Foundation 
Venue: MQI, 28 Winetavern Street, Dublin 8
Organised by / Contact: Merchants Quay Ireland / Miriam 
Kane
Email: training@mqi.ie
Tel: (01) 524 0934
Information: This course is aimed towards project workers, 
health care workers, social workers, people working in 
community settings and other who are interested in gaining 
a basic level of understanding of the main issues and 
concepts relating to problem drug use in Ireland. The aim of 
the course is to raise awareness and introduce participants 
to key issues associated with problem drug use. Participants 
completing this course will have a sound understanding of 
various drugs including how they are used, the equipment 
involved, common terminology, drug effects and the 
patterns of drug use. Participants will also have gained an 
understanding of their own personal attitudes regarding 
drug use and that of others and an appreciation of the policy 
and practice of harm reduction.
24 April 2013
Legal Highs/Research Chemicals Training
Venue: Oxford House, Bethnal Green, London E2 6HG
Organised by / Contact: Tony d’Agostino
Email: tonydaguk@gmail.com
www.tonydagostino.co.uk/drug-training-events.htm
Information: A one-day course, at beginner to intermediate 
level, on mephedrone, methoxetamine (MXE), synthetic 
cannabinoids and other commonly used legal / illegal 
drugs. This course focuses on the different types of research 
chemicals, prevalence, health and interventions. 
May
7–10 May 2013
Global Addiction and Europad Joint Conference
Venue: Pisa, Italy
Organised by / Contact: Global Addiction / Cortex Ltd
Email: mc@cortexcongress.com
www.globaladdiction.org/
Information: Global Addiction is a knowledge-sharing 
facility for all those involved in the understanding and 
treatment of addiction. It offers the opportunity for all to link 
both on-line and at the biennial conference. This year we are 
pleased to launch our new Policy Considerations stream 
on the website which will develop into a subsection geared 
more towards policy makers, influencers and initiators. This 
section will include topics of relevance more to the wider 
societal aspects of addiction. The open-access part of the 
website is geared towards Clinical Aspects of understanding 
and treating all addictions.
16–17 May 2013
Managing Drug and Alcohol Problems in Primary Care
Venue: National Motorcycle Museum, Birmingham, UK
Organised by / Contact: Royal College of General 
Practitioners
www.rcgp.org.uk/courses-and-events
Information: This, the 18th national conference, will once 
again examine the critical role primary care plays in working 
with drug users, their families and carers. The conference 
is the largest event in the UK for GPs, shared care workers, 
drug users, nurses and other primary care staff, specialists, 
commissioners and researchers interested in and involved 
with the management of drug users in primary care. 
June
9–12 June 2013
The Value(s) of Harm Reduction  
Harm Reduction International Conference 
Venue: Vilnius, Lithuania
Organised by / Contact: Harm Reduction International / 
Eurasian Harm Reduction Network 
Email: conference@ihra.net
www.ihra.net/about-the-event-2 
Information: Harm Reduction International (HRI) was 
formerly known as the International Harm Reduction 
Association (IHRA). The theme of this conference calls on 
the urgent need to provide sufficient political and financial 
support to address the HIV epidemic driven by injecting 
drug use in many parts of the world, as well as the ethical 
basis of the harm reduction philosophy. It will focus on key 
issues affecting the Eurasian region including the retreat of 
donors, the lack of national government funding for harm 
reduction, the influence of repressive law enforcement 
and human rights abuses that currently take place in the 
countries of Eurasia.
July
1–12 July 2013
Illicit drugs in Europe: supply, demand and public policies 
European Summer School on illicit drugs Europe
Venue: Lisbon, Portugal
Organised by / Contact: University Institute of Lisbon, with 
the EMCDDA
Email: drugsummerschool.cies@iscte.pt
www.drugsummerschool.cies.iscte-iul.pt/np4/home
Information: Two-week summer school in Lisbon on the 
drugs problem in Europe and beyond, involving scientific 
experts from the European Monitoring Centre for Drugs and 
Drug Addiction and the following guest lecturers: Prof Björn 
Hibell, Prof Robert West and Dr Gabriele Fischer. This course 
counts for 6 ECTS Credits for undergraduate and graduate 
students.
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21–23 August 2013
Contemporary Drug Problems Conference  
Complexity: Researching alcohol and other drugs in a 
multiple world
Venue: Aarhus University, Denmark 
Organised by / Contact: Aarhus University Conference 
organisers
Email: CDP@curtin.edu.au
www.psy.au.dk/en/research/research-centres-and-units/
centre-for-alcohol-and-drug-research/research/conferences/
contemporary-drug-problems/ 
Information: An interdisciplinary conference for 
international researchers in drug use and addiction studies 
from a range of research disciplines. This conference offers 
a forum in which the issues and dilemmas of complexity 
in alcohol and other drug research can be explored. It 
welcomes research based on quantitative and qualitative 
methods, and encourages innovative use of methods, 
concepts and theoretical approaches. Following the 
conference, Contemporary Drug Problems, an interdisciplinary 
quarterly and one of the driving forces behind the 
conference, will publish a special issue featuring selected 
papers from the conference.
September
17–20 September 2013
14th conference of the European Federation of 
Therapeutic Communities 
Venue: Prague, Czech Republic
Organised by / Contact: EFTC
Email: eftc@conference.cz
www.conference.cz/EFTC2013/index.htm
Information: This conference will be hosted by the non-
governmental organisation for the treatment of addiction, 
Magdaléna, ops, and the Clinic of Addictology, First Faculty 
of Medicine, Charles University, Prague. Prague is the 
historical pearl of Europe and one of the most beautiful cities 
in the world.
The purpose of the conference is to discuss the pressing 
issues we all face in this changing world of addiction: 
development trends in the therapeutic community; research 
and education; and special populations and approaches. 
This topic not only invites us to reflect upon the basic and 
classical therapeutic ideas from a contemporary perspective, 
but also proposes to discuss their current transformation, 
modification, and new developments.
October
23–26 October 2013 
Addictions and other Mental Disorders  
Third International Congress on Dual Disorders
Venue: Barcelona, Spain 
Organised by / Contact: Spanish Society of Dual Disorders 
(SEPD) 
Email: secretariat@cipd2013.com 
www.patologiadual.es/cipd2013/index.htm
Information: This multidisciplinary congress is expected 
to attract in excess of 1,500 mental health professionals, 
researchers, educators, healthcare workers, administrators, 
policy makers, academics, consumers, careers and field 
workers from across the globe. After the successful second 
congress held in Barcelona in 2011, the aim of this new 
edition is to consolidate a platform on which professionals 
in the field of mental health and addictions, together 
with the main opinion leaders in this area, can review and 
share recent knowledge and developments. The themes 
to be addressed are the etiopathogenesis, diagnosis and 
therapeutics of dual disorders, from molecular biology to 
daily clinical practice and from prevention strategies to 
recovery programmes.
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